IOVA Stock Analysis: Buy, Sell, or Hold?
IOVA - Iovance Biotherapeutics, Inc. Common Stock
$8.17
0.16 (2.00%)
▲
5d:
+1.36%
30d:
+100.74%
90d:
+106.31%
WAIT
LOW Confidence
Analysis Updated: Aug 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 7, 2026 at $6.34 · last confirmed Aug 28, 2026
Strength: 6.6/10
Get Alerted When IOVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IOVA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IOVA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IOVA is currently trading at $8.17, which is considered extended relative to its 30-day fair value range of $4.89 to $7.97.
Technical Outlook: Technically, IOVA is in a strong uptrend. Immediate support is located at $6.93, while resistance sits at $9.36.
Market Sentiment: IOVA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+22.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IOVA is in a strong uptrend. Immediate support is located at $6.93, while resistance sits at $9.36.
Market Sentiment: IOVA scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+22.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.89 -
$7.97
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 22.4% below Wall St target ($10.00)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.89 -
$7.97
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$6.93
Resistance Level
$9.36
Current Trend
Strong Uptrend
Technical data as of
Aug 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.44
Wall Street Target
$10.00
(+22.4%)
Revenue Growth (YoY)
65.7%
Profit Margin
-89.1%
Share & Embed Analysis
Last updated: August 31, 2026 7:43 PM ET
Data refreshes hourly during market hours. Next update: 8:43 PM
Data refreshes hourly during market hours. Next update: 8:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IOVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 49 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1176 | 42 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 41 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$287 | 59 HOLD |
